4.8 Meeting Abstract

MAGELLAN-1, Part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic hepatitis C virus genotype 1 or 4 and prior direct-acting antiviral treatment failure

Journal

JOURNAL OF HEPATOLOGY
Volume 66, Issue 1, Pages S83-S84

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/S0168-8278(17)30432-4

Keywords

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available